Drug Profile
CNS disorders therapeutic - Curia/Bristol-Myers Squibb
Alternative Names: Triple reuptake inhibitorLatest Information Update: 13 Oct 2021
Price :
$50
*
At a glance
- Originator AMRI
- Developer Bristol-Myers Squibb; Curia
- Class
- Mechanism of Action Biogenic amine uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II CNS disorders
Most Recent Events
- 09 Sep 2016 CNS disorders therapeutic is still in phase II development for CNS disorders (AMRI pipeline, September 2016)
- 25 May 2011 Phase-II clinical trials in CNS disorders (unspecified route)